ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

rilvegostomig

Also written as “Rilvegostomig”, “AZD2936” and “AZD9592 + Rilvegostomig”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Biliary Tract Neoplasms · Carcinoma, Hepatocellular · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.

Drug pageRilvegostomig: every studyAll 31 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 26, 202324 company-led studies, 23 open or runningNext primary completion: May 4, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only2222 open or runningphase 3since Oct 26, 2023Dec 13, 2018May 4, 2027phase 2 · NCT04379596
Presage Biosciences21 open or runningearly phase 1since Sep 1, 2020Sep 1, 2020Dec 2031early phase 1 · NCT04541108
  • Named in AstraZeneca’s own pipeline as rilvegostomig, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: Daiichi Sankyo and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Presage Biosciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 1, 2020First study: early phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT04541108 · 15 enrolled · United States
  2. Jul 21, 2022Named rilvegostomigINNProposed as its International Nonproprietary Name in WHO's List 127 · before, AZD2936
  3. Apr 3, 2024Early phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT06366451 · 17 enrolled · United States

Ahead

  1. Dec 2031Primary completion: early phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT04541108

TargetBeta

“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory …”NCIt, read by Claude
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory mot”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315

Studies

All 2 Presage Biosciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06366451Squamous Cell Carcinoma of Head and Neck · United StatesEarly 1CompletedMar 25, 202617
NCT04541108Squamous Cell Carcinoma of Head and Neck · United StatesEarly 1Active, not recruitingDec 203115

How it is read

Names in the registry

  • “Rilvegostomig”, 20 entries
  • “AZD2936”, 2 entries
  • “AZD9592 + Rilvegostomig”, 2 entries
  • “AZD8205 and AZD2936 (Rilvegostomig)”, 1 entry
  • “AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.